Items Tagged ‘Breast Cancer’

August 1st, 2017

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence

By

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center […]

View full entry

Tags: Breast Cancer, breast surgery, early-stage breast cancer, News, Nipple-Sparing Mastectomy


July 26th, 2017

Balance and Gait is Negatively Impacted By Chemotherapy Treatment

By

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research […]

View full entry

Tags: Balance, Breast Cancer, Chemotherapy, News, side effects


July 18th, 2017

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer

By

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) with early-stage HER2-positive breast cancer […]

View full entry

Tags: Breast Cancer, HER2, neratinib, Nerlynx, News


June 22nd, 2017

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

By

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, durvalumab, immunotherapy, News, precision medicine, Triple Negative Breast Cancer


June 9th, 2017

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer

By

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, keytruda, News, opdivo, PD-1, precision medicine, Triple negative Breast Cancer (TNBC), Yervoy


May 31st, 2017

FDA Approves First-of-its-kind Kisqali® Femara® Co-Pack For Initial Treatment Of HR+/HER2- Advanced or Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the Kisqali ®Femara ® Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women 1. The Kisqali-Femara Co-Pack is the first, and only currently available, combination pack with two prescription products in advanced breast […]

View full entry

Tags: Advanced Metastatic Breast Cancer, Breast Cancer, HER2 neu negative, HR+, Kisqali® Femara®, News


May 16th, 2017

Half of Breast Cancer Patients Pursue Reconstructive Surgery Without Understanding of Risks

By

More than half of breast cancer patients (57 percent) undergoing mastectomy lack the necessary medical knowledge to make a high-quality decision about reconstructive surgery that aligns with their personal goals, suggesting a trend toward overtreatment, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer […]

View full entry

Tags: Breast Cancer, mastectomy, News, Reconstructive Surgery


April 17th, 2017

Breast cancer rates increasing among Asian Americans

By

Researchers examined breast cancer incidence rates among seven Asian American ethnic groups in this new study.  In contrast to other US racial/ethnic groups, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years. To better understand potential contributors to this increase, researchers at the Cancer Prevention Institute of California (CPIC) examined […]

View full entry

Tags: Breast Cancer, News


April 12th, 2017

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer

By

The investigative agent, Tecentriq (atezolizumb), in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both hormone-negative and HER2-negative. Hormone-negative breast cancer refers to a type of breast cancer […]

View full entry

Tags: Breast Cancer, News, precision medicine, Tecentriq, tnbc


March 16th, 2017

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

View full entry

Tags: Breast Cancer, kisqali, Metastatic Breast Cancer, News, riboiclib, Stages II-III Breast Cancer


February 28th, 2017

Chemo-brain Among Women with Breast Cancer is Very Common

By

The largest study to date of a condition known as “chemo-brain” shows that women with breast cancer report it’s a substantial problem after chemotherapy for as long as six months after treatment, according to investigators at the Wilmot Cancer Institute. Scientists have known that cancer-related cognitive impairment, which includes problems with memory, attention, and processing […]

View full entry

Tags: Breast Cancer, chemobrain and chemotherapy side effects, News, Ovarian Cancer


February 15th, 2017

Vaccine Shows Promising Results for Early-Stage Breast Cancer Patients

By

Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Doctors at Moffitt Cancer Center in Tampa Florida are working on a promising new vaccine that would help early-stage breast cancer patients who have HER2 positive disease. The HER2 protein […]

View full entry

Tags: Breast Cancer, News, vaccine


November 15th, 2016

Aromatase Inhibitor–Associated Joint Pain Tends to Resolve Upon Treatment Completion

By

A class of drugs known as aromatase inhibitors (AI) commonly used in the management of estrogen receptor-positive (ER+) breast cancer are associated with troublesome joint pain. In fact, as many as half of women on AI therapy experience joint pain, and 20% become non-compliant with their AI therapy because of side effects.1 The origin of […]

View full entry

Tags: AI, aromatase inhibitors, Breast Cancer, ER-positive, joint pain, News


October 26th, 2016

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

By

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

View full entry

Tags: 2016, Breast Cancer, ESMO, Femera, hormone-receptor positive, HR+ metastatic, letrozole, Metastatic Breast Cancer, MONALEESA-2 clinical, News, ribociclib LEE011


September 7th, 2016

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo

By

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results need to be validated, and compared to other tests in order to confirm findings and determine true clinical utility […]

View full entry

Tags: Breast Cancer, early-stage, hereditary, MammaPrint, News, Stage I Node Negative Breast Cancer